Metabasis Reports Disappointments On Two Pipeline Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase IIb trial of a type 2 diabetes candidate fails to show efficacy over metformin, and Schering-Plough also returns rights to hepatitis b candidate pradefovir.
You may also be interested in...
Metabasis Type 2 Diabetes Candidate Successful In Phase IIa Study
San Diego company wants to partner the second-generation gluconeogenesis inhibitor.
Metabasis Type 2 Diabetes Candidate Successful In Phase IIa Study
San Diego company wants to partner the second-generation gluconeogenesis inhibitor.
Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Execs provide an update on plans for recharging Cesamet following a sluggish launch, and development plans for a new potential entry: retigabine for seizures.